Intravitreal Anti-vascular Endothelial Growth Factor Injections to Treat Neovascular Age-related Macular Degeneration: Long-term Treatment Outcomes
10.3341/jkos.2018.59.12.1142
- Author:
Yu Jeong PARK
1
;
Gi Sung SON
;
Yoon Jeon KIM
;
June Gone KIM
;
Young Hee YOON
;
Joo Yong LEE
Author Information
1. Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. ophthalmo@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Age-related macular degeneration;
Anti-vascular endothelial growth factor;
Choroidal neovascularization
- MeSH:
Anterior Chamber;
Appointments and Schedules;
Choroidal Neovascularization;
Endophthalmitis;
Endothelial Growth Factors;
Follow-Up Studies;
Humans;
Intraocular Pressure;
Macular Degeneration;
Medical Records;
Outpatients;
Ranibizumab;
Retinaldehyde;
Specialization;
Visual Acuity
- From:Journal of the Korean Ophthalmological Society
2018;59(12):1142-1151
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We assessed the visual and anatomical outcomes, and the safety profile of long-term intravitreal anti-vascular endothelial growth factor (VEGF) injections (aflibercept, ranibizumab, and bevacizumab) given to treat neovascular age-related macular degeneration (NAMD). METHODS: We analyzed medical records collected over 7 years of treatment-naive NAMD patients who received outpatient clinic-based intravitreal anti-VEGF injections. All were treated employing either “treat-and-extend” or “as needed” protocols at the discretion of the retinal specialist. The number of injections, adverse events associated with injection, and measures of visual acuity (VA), central foveal thickness (CFT), and intraocular pressure (IOP) were recorded. RESULTS: Overall, we assessed 196 eyes of 196 patients (average age 68.6 ± 9.6 years; 77 females). Patients received an average of 17.3 ± 13.5 injections over 78.0 ± 16.5 months of clinical follow-up. The initial mean VA (logMAR) was 0.75 ± 0.58 and the CFT was 349.7 ± 152.6 µm. Both parameters exhibited maximal improvements at the 6-month visit (p < 0.05). However, the clinical outcomes worsened over the 7-year clinical course; the best-corrected visual acuity (BCVA) was 0.91 ± 0.78 and the CFT was 284.5 ± 105.8 µm at 7 years. The BCVA at 7 years was significantly correlated with the initial BCVA. IOP-related events increased 11-fold and anterior chamber reactions increased 3-fold over the years, but no significant complications such as endophthalmitis were recorded. CONCLUSIONS: The use of intravitreal anti-VEGF agents was associated with initial visual improvements over 6 months but did not prevent the worsening of NAMD over 5 years. The BCVA at the initial visit was a strong predictor of the final BCVA. A more intensive injection schedule might improve long-term outcomes.
